NAGIOS: RODERIC FUNCIONANDO

The Contibution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study

Repositori DSpace/Manakin

IMPORTANT: Aquest repositori està en una versió antiga des del 3/12/2023. La nova instal.lació está en https://roderic.uv.es/

The Contibution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study

dc.contributor.author	Di Forti, Marta
dc.contributor.author	Quattrone, Diego
dc.contributor.author	Freeman, Tom P.
dc.contributor.author	Tripoli, Giada
dc.contributor.author	Gayer-Anderson, Charlotte
dc.contributor.author	Quigley, Harriet
dc.contributor.author	Rodríguez, Victoria
dc.contributor.author	Jongsma, Hannah
dc.contributor.author	Ferraro, Laura
dc.contributor.author	La Cascia, Caterina
dc.contributor.author	La Barbera, Daniele
dc.contributor.author	Tarricone, Ilaria
dc.contributor.author	Berardi, Domenico
dc.contributor.author	Szoke, Andrei
dc.contributor.author	Arango, Celso
dc.contributor.author	Tortelli, Andrea
dc.contributor.author	Velthorst, Eva
dc.contributor.author	Bernardo, Miguel
dc.contributor.author	Del‑Ben, Cristina Marta
dc.contributor.author	Menezes, Paulo Rossi
dc.contributor.author	Selten, Jean-Paul
dc.contributor.author	Jones, Peter B.
dc.contributor.author	Kirkbride, James B.
dc.contributor.author	Rutten, Bart P.F.
dc.contributor.author	De Haan, Lieuwe
dc.contributor.author	Sham, Pak Chung
dc.contributor.author	van Os, J.
dc.contributor.author	Lewis, Cathryn M.
dc.contributor.author	Lynskey, Michael
dc.contributor.author	Morgan, Craig
dc.contributor.author	Murray, Robin
dc.date.accessioned	2021-07-28T18:31:14Z
dc.date.available	2021-07-28T18:31:14Z
dc.date.issued	2019
dc.identifier.citation	Di Forti, Marta Quattrone, Diego Freeman, Tom P. Tripoli, Giada Gayer-Anderson, Charlotte Quigley, Harriet Rodríguez, Victoria Jongsma, Hannah Ferraro, Laura La Cascia, Caterina La Barbera, Daniele Tarricone, Ilaria Berardi, Domenico Szoke, Andrei Arango, Celso Tortelli, Andrea Velthorst, Eva Bernardo, Miguel Del&#8209Ben, Cristina Marta Menezes, Paulo Rossi Selten, Jean-Paul Jones, Peter B. Kirkbride, James B. Rutten, Bart P.F. De Haan, Lieuwe Sham, Pak Chung van Os, J. Lewis, Cathryn M. Lynskey, Michael Morgan, Craig Murray, Robin 2019 The Contibution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study Lancet Psychiatry 6 5 427 436
dc.identifier.uri	https://hdl.handle.net/10550/80068
dc.description.abstract	Background Cannabis use is associated with increased risk of later psychotic disorder but whether it affects incidence of the disorder remains unclear. We aimed to identify patterns of cannabis use with the strongest effect on odds of psychotic disorder across Europe and explore whether differences in such patterns contribute to variations in the incidence rates of psychotic disorder. Methods We included patients aged 18-64 years who presented to psychiatric services in 11 sites across Europe and Brazil with first-episode psychosis and recruited controls representative of the local populations. We applied adjusted logistic regression models to the data to estimate which patterns of cannabis use carried the highest odds for psychotic disorder. Using Europe-wide and national data on the expected concentration of Δ9-tetrahydrocannabinol (THC) in the different types of cannabis available across the sites, we divided the types of cannabis used by participants into two categories: low potency (THC <10%) and high potency (THC ≥10%). Assuming causality, we calculated the population attributable fractions (PAFs) for the patterns of cannabis use associated with the highest odds of psychosis and the correlation between such patterns and the incidence rates for psychotic disorder across the study sites. Findings Between May 1, 2010, and April 1, 2015, we obtained data from 901 patients with first-episode psychosis across 11 sites and 1237 population controls from those same sites. Daily cannabis use was associated with increased odds of psychotic disorder compared with never users (adjusted odds ratio [OR] 3·2, 95% CI 2·2-4·1), increasing to nearly five-times increased odds for daily use of high-potency types of cannabis (4·8, 2·5-6·3). The PAFs calculated indicated that if high-potency cannabis were no longer available, 12·2% (95% CI 3·0-16·1) of cases of first-episode psychosis could be prevented across the 11 sites, rising to 30·3% (15·2-40·0) in London and 50·3% (27·4-66·0) in Amsterdam. The adjusted incident rates for psychotic disorder were positively correlated with the prevalence in controls across the 11 sites of use of high-potency cannabis (r = 0·7; p=0·0286) and daily use (r = 0·8; p=0·0109). Interpretation Differences in frequency of daily cannabis use and in use of high-potency cannabis contributed to the striking variation in the incidence of psychotic disorder across the 11 studied sites. Given the increasing availability of high-potency cannabis, this has important implications for public health.
dc.relation.ispartof	Lancet Psychiatry, 2019, vol. 6, num. 5, p. 427-436
dc.subject	Drogues
dc.subject	Cannabis
dc.subject	Salut mental
dc.title	The Contibution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study
dc.type	journal article	es_ES
dc.date.updated	2021-07-28T18:31:14Z
dc.identifier.doi	10.1016/S2215-0366(19)30048-3
dc.identifier.idgrec	131806
dc.rights.accessRights	open access	es_ES